文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > 2014+WHF专家共识声明:东亚ACS或接受PCI治疗患者的抗血小板治疗
侵权投诉

2014+WHF专家共识声明:东亚ACS或接受PCI治疗患者的抗血小板治疗

英文版

CONSENSUS

STATEMENTS

EXPERT CONSENSUS DOCUMENT

World Heart Federation expert consensus

statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI

Glenn N. Levine, Young-Hoon Jeong, Shinya Goto, Jeffrey L. Anderson, Yong Huo, Jessica L. Mega, Kathryn Taubert and Sidney C. Smith Jr

Abstract | Guideline recommendations on the use of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention (PCI) have been formulated by both the ACC/AHA and the ESC. These recommendations are based primarily on large,

phase III, randomized, controlled trials of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor. However, few East Asian patients have been included in the trials to assess the use of these agents, particularly the newer agents prasugrel and ticagrelor. Additionally, an increasing body of data suggests that East Asian patients have differing risk profiles for both thrombophilia and bleeding compared with white patients, and that a different ‘therapeutic window’ of on treatment platelet reactivity might be appropriate in East Asian patients. Furthermore, a phenomenon referred to as the ‘East Asian paradox’ has been described, in which East Asian patients have a similar or even a lower rate of ischaemic events after PCI compared with white patients, despite a higher level of platelet reactivity during DAPT. Recognizing these concerns, the World Heart Federation has undertaken this evidence based review and produced this expert consensus statement to determine the antiplatelet treatment strategies that are most appropriate for East Asian patients.

Levine, G. N. et al. Nat. Rev. Cardiol. advance online publication 26 August 2014; Introduction

Baylor College of

Medicine and Michael E. DeBakey VA Medical Center, USA (G.N.L.). Gyeongsang National University Hospital and Gyeongsang National University School of Medicine, South Korea (Y. H.J.). Department of Medicine (Cardiology), Tokai University School of Medicine, Japan (S.G.). Intermountain Medical Center, University of Utah School of Medicine, USA (J.L.A.). Department of Cardiology, Peking University First

Hospital, China (Y.H.). Brigham and Women’s Hospital, TIMI Study Group, USA (J.L.M.). World Heart Federation, Switzerland (K.T.). Division of Cardiology, University of North Carolina, 160 Dental Circle, CB 7075,

Chapel Hill, NC 27599, USA (S.C.S.).Correspondence to: S.C.S.

At the 65th World Health Assembly in May 2012, all 194 WHO member states endorsed a target to reduce pre-mature deaths caused by noncommunicable diseases by 25% by 2025.1 Cardiovascular diseases are the leading cause of death and disability among the noncommuni-cable diseases.2 Therefore, effective treatment of patients with atherosclerotic coronary artery disease—both those with acute coronary syndrome (ACS) and those under-going percutaneous coronary intervention (PCI)—is an important strategy to reduce the rate of premature death

Competing interests

Y. H.J. has received honoraria for lectures from AstraZeneca, Daiichi Sankyo/Lilly, Haemonetics, Nanosphere, Otsuka, and Sanofi Aventis; and research grants or support from Accumetrics, Boehringer Ingelheim, Han mi Pharmaceuticals, Haemonetics, and Otsuka. S.G. has received honoraria from Asteras, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Medtronic Japan, Mochida, MSD, Novartis, Otsuka, Pfizer, Sanofi Aventis, Takeda, and Tanabe Mitsubishi. He is an advisory board member for AstraZeneca, Bayer, MSD, and Pfizer/BMS. He is an investigator on a study or trial sponsored by AstraZeneca, Bayer, MSD, and Pfizer/BMS. J.L.A. served on an Acute Coronary Syndrome (ACS) Expert Panel to generate a position paper on advances in ACS therapy that was funded by an unrestricted educational grant from Sanofi Aventis (France). J.L.M. served as an investigator on a study or trial sponsored by Accumetrics, AstraZeneca, Bayer Healthcare, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Johnson & Johnson, Nanosphere, and Sanofi Aventis. G.N.L., Y.H., K.T., and S.C.S. declare no competing interests.

from cardiovascular disease as well as global mortality associated with noncommunicable diseases.

Compelling evidence supports the use of dual anti-platelet therapy (DAPT) in patients with ACS and also those with stable ischaemic heart disease undergoing PCI. In these clinical settings, the use of a P2Y12 inhibi-tor combined with aspirin is recommended in the ACC/AHA and ESC guidelines.3–7 These recommendations are based primarily on large, phase III, randomized, con-trolled trials of these agents. In addition, patients who are poor responders or who have a high on-treatment plate-let reactivity to ADP during DAPT are at increased risk of ischaemic events after PCI.8 Multiple lines of evidence have suggested that low on-treatment platelet reactivity to ADP is associated with an increased risk of bleeding.8 Therefore, a ‘therapeutic window’ concept of platelet reactivity has been proposed for P2Y12-inhibitor therapy. However, the relationship between platelet reactivity and ischaemic or bleeding events might differ according to intrinsic thrombogenicity or disease activity.9

As with most cardiovascular drugs, P2Y12 inhibitors have shown marked interethnic differences in pharmaco-kinetic and pharmacodynamic profiles.9 Although East Asian ethnic groups are among the most populous (more than 1.5 billion people), very few East Asian patients have been included in the trials to assess the use of P2Y12 inhibitors, particularly the newer agents prasugrel and

第1页

TOP相关主题

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email